大洋洲 · 股市与财经 · The Motley Fool Australia
CSL unveils exclusive Alentis deal to advance rare disease treatments
CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy. The post CSL unveils exclusive Alentis deal to advance rare disease…
在 The Motley Fool Australia 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.fool.com.au)
